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analyses confirmed that the exposure at the recommended 
Phase 2 dose (RP2D) of 400 mg BID was comparable with 
exposures previously reported in non-Japanese subjects. 
Durable stable disease of approximately 24 weeks was con-
firmed in two subjects (malignant mesothelioma and rectal 
cancer).
Conclusions VS-6063 was well tolerated at all dose levels 
investigated in this first-in-Asian study. These data support 
the administration of VS-6063 to Japanese subjects at the 
RP2D in clinical trials involving solid tumor malignancies.
Keywords Focal adhesion kinase · Proline-rich tyrosine 
kinase-2 · First-in-Asian phase 1 study · VS-6063 · 
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Introduction
High expression of focal adhesion kinase (FAK) has been 
frequently demonstrated to be associated with invasive and 
metastatic malignancies, implicating FAK in malignant 
progression of multiple epithelial tumors [1–6]. FAK local-
izes to focal adhesions and mediates physical attachment 
of cells to the extracellular matrix (ECM). Focal adhesion 
kinase is known to promote tumor cell survival and resist-
ance to anoikis (induction of apoptosis upon loss of con-
tact with the ECM), via the ADRB2/Src signaling pathway. 
The ability to survive without ECM contact is a hallmark 
of metastatic cells, allowing them to leave the parent tumor 
and migrate to and colonize distant tissues. This ability is 
also characteristic of a subpopulation of highly tumorigenic 
cells which possess qualities like stem cell. These cells 
are considered to be cancer stem cells (CSC) or cancer or 
tumor initiating cells (CIC or TIC) and may be defined 
as malignant cells with a stem cell phenotype [7]. Tumor 
Abstract 
Purpose VS-6063 (also known as defactinib or 
PF-04554878) is a second-generation inhibitor of focal 
adhesion kinase and proline-rich tyrosine kinase-2. This 
phase 1 study evaluated the safety and tolerability, phar-
macokinetics, and clinical activity of VS-6063 in Japanese 
subjects with advanced solid tumor malignancies in a first-
in-Asian study setting.
Methods VS-6063 was administered orally twice daily 
(b.i.d.) in 21-day cycles to cohorts of three subjects each 
with a standard 3 + 3 dose-escalation design until dis-
ease progression or unacceptable toxicity. Blood samples 
for pharmacokinetics were collected on Day 1 and 15. 
The assessments were performed using CTCAE v4.0 for 
adverse events (AEs), and the Response Evaluation Crite-
ria In Solid Tumors, version v1.1 (RECIST v1.1) for tumor 
response.
Results Nine patients were treated across three dose lev-
els (200–600 mg BID). No dose-limiting toxicities were 
observed at any dose level. Most frequent treatment-related 
AEs were Grade 1/2 unconjugated hyperbilirubinemia, 
fatigue, decreased appetite, and diarrhea. Only one sub-
ject in the 200 mg BID cohort experienced reversible and 
transient Grade 3 unconjugated hyperbilirubinemia. PK 
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growth thus occurs by propagation of these cells, and CSC 
have been implicated in tumor initiation, progression, 
metastasis, and drug resistance. This mechanism of meta-
static dissemination has recently been shown to involve the 
formation of filopodium-like protrusions and the subse-
quent establishment of elongated, mature adhesion plaques 
which contribute critically to the rapid proliferation of the 
micrometastatic cells within the new environment [8]. In 
these studies, activation of FAK was shown to be a critical 
protein involved in the proliferation of these cells. Taken 
together these data suggest that FAK modulation may be a 
potential therapeutic target for cancer.
VS-6063 (defactinib) is a small molecule, orally avail-
able potent adenosine 5′-triphosphate (ATP)-competitive, 
reversible inhibitor of FAK and proline-rich tyrosine 
kinase-2 (Pyk2). FAK and Pyk2 are members of the same 
family of nonreceptor protein tyrosine kinases sharing sig-
nificant sequence homology and are implicated as impor-
tant integrating molecules in signal transduction cascades. 
VS-6063 produces potent in vitro inhibition of recombi-
nant human FAK and Pyk2 activity (inhibitory concentra-
tion of 50 % [IC50] = 0.6 nM for each kinase), display-
ing more than 100-fold greater selectivity for FAK and 
Pyk2 than for other nontarget kinases. Toxicology studies 
conducted with VS-6063 have identified the liver and gall 
bladder, gastrointestinal tract, hematopoietic system, testes/
epididymis, and cardiovascular system as potential targets. 
Importantly, preclinical evidence indicates that VS-6063 
has a low potential for CYP 2C-, 2D- or 3A-mediated drug 
interactions. Based on both these preclinical findings and 
previous first-in-human (FIH) experience of phase 1 study 
in subjects with advanced solid tumors in USA [9], a first-
in-Asian phase 1 dose-escalation study was conducted 
to determine the MTD and overall safety and tolerability 
of VS-6063, and to identify a recommended phase 2 dose 
(RP2D) in Japanese patients with non-hematologic malig-
nancies. Secondary objectives included characterization of 




All subjects provided informed consent, and the study 
was conducted in accordance with both the Declaration 
of Helsinki and Good Clinical Practices (GCP), includ-
ing the archiving of essential documents. The study was 
approved by the institutional review board of study site, 
and this study was registered at ClinicalTrials.gov as 
NCT01943292. The main eligibility criteria were as fol-
lows: Japanese patient with histologically or cytologically 
confirmed diagnosis of locally advanced or metastatic solid 
tumor malignancies that had experienced disease progres-
sion on, were intolerant of, or not eligible for standard 
therapy; aged 20 years or older; an Eastern Cooperative 
Oncology Group (ECOG) performance status of 0 or 1; 
and adequate hematologic, hepatic, and renal functions. 
Key exclusion criteria included cancer-directed therapy 
(chemotherapy, radiotherapy, hormonal therapy, biologic, 
or immunotherapy, etc.) within 28 days of the first dose of 
study drug or 5 half-lives, whichever was shorter, a gastro-
intestinal condition which could have interfered with the 
swallowing or absorption of study medication, corrected 
QT interval (QTc) ≥470 ms (as calculated by the Frideri-
cia correction formula), uncontrolled or severe concurrent 
medical condition (including uncontrolled brain metas-
tases), and uncontrolled or severe cardiovascular disease. 
Potent CYP3A4 inhibitors or inducers and systemic antico-
agulation were prohibited.
Study design and treatment
This was a phase 1, open-label, dose-escalation study to 
evaluate the safety and PK of VS-6063, a FAK inhibitor 
in Japanese subjects with advanced solid tumor malignan-
cies. This study was expected to enroll up to 18 evaluable 
subjects with non-hematologic malignancies if 6 sub-
jects were assigned at each of the 3 planned dose levels 
of 200, 400, and 600 mg BID. VS-6063 was administered 
orally, BID, in continuous 21 day cycles. Subject enroll-
ment proceeded according to a standard 3 + 3 design. In 
the absence of DLT, each subject received oral VS-6063 
(BID) for a minimum of 21 days of continuous daily dos-
ing (1 cycle) and could continue to receive additional 
cycles of study treatment until disease progression was 
documented or other treatment discontinuation criteria 
were met. All patients within a cohort were required to 
complete 1 cycle (21 days) of dosing with <1 of 3 or <2 
of 6 subjects experiencing a DLT prior to escalation to the 
next dose level in a new cohort. Three subjects were to be 
treated at each dose level until the first instance of DLT, 
after which up to 6 subjects were to be treated at that dose 
level. If a second DLT was observed in up to 6 subjects, 
the DLT dose level was reached. DLTs included Grade 4 
neutropenia lasting ≥7 days without growth factor sup-
port; Grade ≥3 febrile neutropenia; Grade 4 thrombocy-
topenia, Grade 3 or 4 nonhematologic toxicities (exclud-
ing nausea, vomiting, or diarrhea unless uncontrolled with 
supportive care), Grade ≥3 QTc interval prolongation, or 
any treatment-related toxicities that resulted in failure to 
receive at least approximately 85 % of the planned doses 
for that cycle (e.g., failure to complete at least 18 days 
of treatment in a continuous 21-day regimen) despite 
maximal (as judged by the investigator) supportive care 
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measures. The MTD was defined as the highest dose level 
studied at which <1 subject out of 3 or <2 subjects out 
of 6 experienced a DLT. The RP2D was to be determined 
in discussion among the sponsor, medical monitor, and 
investigators. Observations related to PK and any VS-
6063-related toxicities were included in the rationale sup-
porting the RP2D. Safety and tolerability was assessed 
by the incidence and severity of AEs as determined by 
National Cancer Institute (NCI) Common Terminology 
Criteria for Adverse Events (CTCAE v4.03). The anti-
tumor activity of study treatment was assessed accord-
ing to the Response Evaluation Criteria in Solid Tumors 
(RECIST v1.1).
Pharmacokinetic assessments
Blood sampling and processing
Pharmacokinetic samples were to be collected for deter-
mination of VS-6063 concentration and potential metab-
olites at the time points of Pre-dose (within 30 min of 
VS-6063 dosing), postdose (15 min, 30 min, and 1, 2, 4, 8, 
12, and 24 h after VS-6063 administration) during Cycle 
1 on Days 1 and 15. The analytical laboratory measured 
plasma concentrations using a validated method. Phoe-
nix WinNonlin (v 6.3, Pharsight Inc., Mountain View, 
CA) was used to estimate all pharmacokinetic parameters 
using the non-compartmental analysis tool and the plasma 
model. Cmax and Tmax were determined by direct assess-
ment (no calculations) of the concentration versus time 
data. All AUC calculations followed the linear trapezoi-
dal rule. As data permitted, the terminal elimination rate 
constant (lambda z, λz) for VS-6063 data was calculated. 
Lambda z was determined by the slope of the regression 
line of the natural log transformed concentrations versus 
time with at least three data points not including the Cmax 
and a correlation coefficient (R2) of regression >0.90. 
In instances where the λz range was not at least twofold 
greater than the calculated half-life, the resulting values 
(AUCINF, CL/F and Vz/F) were deemed unreliable and 
were not reported, although the half-life will be calcu-
lated and reported if the λz range met the R2 requirements. 
The following PK parameters were to be calculated: oral 
clearance (CL/F), maximum concentration (Cmax), Tmax, 
half-life (T1/2), area under the curve (AUC), and other 
relevant parameters.
Urine collection and sampling
To assess the elimination of VS-6063 and its potential 
metabolites, total 24-h urine output was to be collected on 




A total of 9 subjects received VS-6063 between September 
2013 and June 2014. All were Asian (of Japanese descent). 
The study population was predominantly male (77 %), with 
an ECOG performance status of 0 or 1 (100 %). The most 
common cancer type was rectal cancer (3 patients). Other 
cancer types, including esophageal, lung, mesothelioma, 
Paget’s carcinoma, colon, and thymic cancer, were each 
reported in 1 subject. Eight subjects overall had received 
prior systemic therapy for their cancer, with a median of 7 
prior therapies across dose cohorts. Six subjects, 2 in each 
dose cohort, had prior surgery. Only 1 subject, in the 200 mg 
cohort, had received prior radiation therapy (Table 1).
Safety and tolerability
Treatment-related adverse events (AEs) occurring in at 
least two subjects are summarized in Table 2. The most 
commonly reported AEs overall were unconjugated hyper-
bilirubinemia (7 patients, 78 %), fatigue (6 patients, 67 %), 
decreased appetite (4 patients, 44 %), and diarrhea (3 
patients, 33 %). Only one patient in the 200 mg dose cohort 
experienced a Grade 3 AE of unconjugated hyperbilirubine-
mia. All other toxicities were manageable and were predom-
inantly mild in intensity (Grade 1 or Grade 2) in severity. 
Table 1  Baseline characteristics of the patients (n = 9)
ECOG Eastern Cooperative Oncology Group











 Colorectal cancer 4
 Esophageal cancer 1
 Mesothelioma 1
 NSCLC 1
 Thymic cancer 1
 Extramammary Paget’s disease 1
No. of prior systemic therapy
 Median 7
 Range 0–13
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There were no AEs leading to death or SAEs, and no AEs 
leading to early study withdrawal. No DLTs were reported 
in any dose cohort. Hyperbilirubinemia was asymptomatic 
and its onset typically occurred within the first 2 weeks of 
initiating treatment. Patients with Grade 1 or 2 unconjugated 
hyperbilirubinemia were able to continue dosing, although 
bilirubin levels tended to fluctuate during treatment. Hyper-
bilirubinemia was reported across all dose cohorts, for 
3 (100 %) patients in the 200 mg dose cohort, 2 (67 %) 
patients in the 400 mg dose cohort, and 2 (67 %) patients 
in the 600 mg dose cohort. One event of hyperbilirubinemia 
(200 mg cohort) was Grade 3 in severity. This patient had 
Grade 1–2 hyperbilirubinemia starting on Day 7; the Grade 
3 event began on Day 42 and resolved 6 days after onset 
following interruption of study drug. All reports of hyper-
bilirubinemia were considered to be related to defactinib. 
None of these subjects had concurrent increases in ALT or 
AST above ULN. The most common events of gastrointes-
tinal disorders were diarrhea reported in 3 (33 %) subjects 
and nausea reported in 2 (22 %). Diarrhea was reported in 
1 (33 %) subject in the 400 mg dose cohort and 2 (67 %) 
subjects in the 600 mg dose cohort. Nausea was reported in 
1 (33 %) subject in the 200 mg dose cohort, and 1 (33 %) 
subject in the 600 mg dose cohort. Both reports of nausea 
were mild in severity as were 2 of the 3 reports of diarrhea; 
1 subject in the 600 mg group experienced diarrhea of mod-
erate intensity. No clinically meaningful changes in any 
ECG parameter were observed for any dose cohort and no 
subject had a QTc interval ≥500 ms or QTc increase from 
baseline >30 ms.
Pharmacokinetics
VS-6063 was rapidly absorbed, with median Tmax observed 
at 2.0 h (range 0.5–4.0 h) postdose following oral doses of 
200–600 mg BID. Plasma VS-6063 exposure (Cmax and 
AUC) increased in a less than dose proportional manner 
and the mean AUC0-12 and AUC0-24 values remained 
relatively consistent across the full dose range evaluated 
(Fig. 1). Doses above 400 mg BID did not result in a sig-
nificant increase in VS-6063 exposure. A similar Cmax was 
observed in the 400 and 600 mg BID dose cohorts on both 
Days 1 and 15 and mean AUC values were relatively con-
sistent across the 200–600 mg BID dose range. Clearance 
appeared to be increased with dose on both Days 1 and 15, 
which is consistent with the less than dose proportional 
increase in exposure. Median half-life values ranged from 
2.3 to 4.3 h across all dose regimens and both PK study 
days. The Day 1 mean CL/F values were 45.6, 105, and 
204 L/h for the 200, 400, and 600 mg doses, respectively. 
The Day 15 mean CL/F values were 32. 1, 70, and 123 L/h 
for the 200, 400, and 600 mg doses, respectively (Table 3). 
VS-6063 was detected in the urine of all patients and 
appeared consistent across all dose cohorts. The mean renal 
clearance (CLr) values ranged from 0.0855 to 0.179 L/h, 
and the percent relative to the total dose administered 
ranged from 0.0439 to 0.356 %. All 9 subjects had systemic 
concentrations of the 4 metabolites of VS-6063 that were 
evaluated (M2, M3, M4, and M5). Median plasma Tmax val-
ues for all metabolites were observed at 2.0–4.0 h postdose 
administration for all cohorts on both PK sampling days. 
Based on the relative plasma Cmax and AUC0-12 values for 
the metabolites compared to VS-6063 values, M2 was the 
most abundant metabolite, followed by M4, M3, and then 
M5. Both the M2 and M4 exposures appeared to be >10 % 
of the parent exposure, while M3 and M5 had exposures 
that were <10 % of the parent exposure. In the urine, the 
M2 metabolite was the most abundant and was excreted in 
amounts greater than the parent compound.
Antitumor activity
The best response overall was stable disease for 3 
(33 %) out of 9 subjects, 1 subject in each dose cohort. 
Table 2  Treatment-related 
adverse events occurring in at 
least 2 subjects
VS-6063 dose cohort Total
N = 9









Blood bilirubin increased 3 (100.0) 2 (66.7) 2 (66.7) 7 (77.8)
Fatigue 2 (66.7) 1 (33.3) 3 (100.0) 6 (66.7)
Decreased appetite 2 (66.7) 1 (33.3) 1 (33.3) 4 (44.4)
Diarrhea 0 1 (33.3) 2 (66.7) 3 (33.3)
Aspartate aminotransferase increased 1 (33.3) 0 1 (33.3) 2 (22.2)
Blood alkaline phosphatase increased 2 (66.7) 0 0 2 (22.2)
Nausea 1 (33.3) 0 1 (33.3) 2 (22.2)
Headache 0 1 (33.3) 1 (33.3) 2 (22.2)
Anemia 0 0 2 (66.7) 2 (22.2)
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Remarkably, durable stable diseases by RECIST crite-
ria were maintained for 169 days (24 weeks) in a subject 
with mesothelioma in the 400 mg cohort, and for 162 days 
(23 weeks) in a subject with rectal cancer in the 600 mg 
dose cohort. The overall median time to disease progres-
sion for all subjects was 63 days (9 weeks) and ranged 
from 61 to 64 days across dose cohorts.
Discussion
This was a first-in-Asian phase 1, open-label, dose-esca-
lation study to evaluate the safety and PK of VS-6063 
in subjects of Japanese descent with non-hematologic 
malignancies. The overall purpose of this phase 1 study 
was to support the development of VS-6063 as an oral 
Fig. 1  Steady-state serum VS-6063 concentration–time profiles over 
the 12-h dose interval (VS-6063 doses 200–600 mg twice daily). 
PK analysis of previous first-in-human phase 1 study revealed that 
VS-6063 dose of 163 mg twice daily (per 70-kg person) is projected 
to achieve a steady-state average plasma concentration equivalent to 
the predicted efficacious free (non-protein-bound) plasma concen-
tration of 13.3 ng/mL required to produce 50 % inhibition of tumor 
pFAK activity in humans
Table 3  Serum pharmacokinetic parameters of VS-6063 in Japanese patients with advanced solid tumors on Day 1 and Day 15
AUC0–12h, area under the concentration–time curve from time zero to 12 h (dosing interval); AUC0–∞, are under the concentration–time curve 
from time zero to infinity; Cmax, maximum observed serum concentration; CV, coefficient of variation; PK, pharmacokinetic; t1/2 elimination 
half-life; Tmax, time of maximum observed serum concentration; GM, Geometric mean
* N = 2; therefore, individual values are presented
















Day 1 0.63 (0.11) 2 (0.5, 4) 3.78 (153) 4.39 (175) 4.3 (3.5, 5.5) 288 (144) 45.6 (175)
Day 15 0.93 (55) 2 (1, 4) 6.24 (90) NA 2.95 (2.9, 3.0) 334, 99.6* 32.1 (90)
400 mg BID
n = 3
Day 1 0.67 (333) 2 (2, 4) 3.37 (159) 3.84 (131) 2.45 (2.3, 3.5) 410 (189) 105 (133)
Day 15 0.96 (218) 2 (1, 4) 5.71 (136) NA 3.0 (2.89, 3.11) 174 (63.5) 70 (136)
600 mg BID
n = 3
Day 1 0.61 (319) 2 (1, 2) 2.68 (269) 3.0 (232) 2.79 (1.33, 5.24) 790 (576) 204 (242)
Day 15 0.98 (216) 2 (2, 4) 4.88 (322) NA 2.27 (1.58, 2.95) 158, 3060* 123 (322)
1002 Cancer Chemother Pharmacol (2016) 77:997–1003
1 3
formulation for the treatment of Asian (Japanese) subjects 
with advanced solid tumors. The doses and regimen pro-
posed for this study were based on both nonclinical data 
and findings of the FIH phase 1 study. The rationale for a 
BID schedule was based on nonclinical data supporting 
the requirement for prolonged suppression of the target for 
maximal efficacy and the observed human half-life of 9.0 h. 
In the previous FIH phase 1 study, subjects received doses 
of 12.5–750 mg of defactinib BID for continuous 21 day 
cycles. PK exposure of VS-6063 at the RP2D of 400 mg 
BID was consistent with previously reported data in non-
Japanese patients. Doses above 400 mg BID did not result 
in a significant increase in VS-6063 exposure. Available 
data indicate that 400 mg BID should result in adequate 
plasma concentration levels to suppress FAK activity.
Following the first-generation FAK inhibitor drug devel-
opment including PF-00562271 [10], early drug develop-
ment of several potent selective second-generation FAK 
inhibitors has been progressed recently. In the phase 1 
dose-escalation study of another second-generation FAK 
inhibitor BI 853520, both proteinuria and fatigue were 
dose-limiting (Grade 3) at the higher doses [11, 12]. In this 
study, no subject developed any grade of proteinuria; never-
theless, the most common AE in the general disorders was 
fatigue reported in 6 (67 %) subjects. Fatigue was reported 
across all dose cohorts with 2 (67 %) subjects in the 200 mg 
dose cohort, 1 (33 %) subject in the 400 mg dose cohort, 
and 3 (100 %) subjects in the 600 mg dose cohort. One 
subject in the 400 mg dose cohort had an interruption in 
study drug for 13 days because of moderate fatigue begin-
ning on Day 78. All other reports of fatigue were mild in 
severity. Regarding safety, increased bilirubin was the most 
commonly reported laboratory abnormality across all dose 
cohorts. Most patients had at least one Grade 1 or Grade 
2 unconjugated hyperbilirubinemia. Transient increases 
in total bilirubin were most pronounced at C1D8; how-
ever, values for all affected subjects trended toward normal 
range by the end of the study. In only 1 of the 9 subjects, 
a dose modification was required for increased bilirubin. 
The increases observed in blood bilirubin did not appear to 
be dose related, and were transient and/or sporadic. There 
was no increase in ALT or AST values associated with the 
increases in bilirubin. The current hypothesis for occur-
rence of unconjugated hyperbilirubinemia with VS-6063 is 
that either the parent compound and/or its metabolite com-
pete with bilirubin for hepatic conjugation and elimination. 
Of note, both VS-6063 and its metabolites are UGT1A1 
inhibitors in vitro. VS-6063 is metabolized in the liver by 
oxidative metabolism and its metabolite undergoes glu-
curonide conjugation via uridine diphosphate glucurono-
syltransferase (UGT) 1A1, the hepatic enzyme primarily 
responsible for conjugation of bilirubin [13, 14].
In pharmacokinetics analysis, VS-6063 was rapidly 
absorbed, with median Tmax observed at 2 h postdose fol-
lowing oral doses of 200–600 mg BID. Plasma VS-6063 
exposure (Cmax and AUC) was less than dose proportional 
and doses above 400 mg BID did not result in a significant 
increase in VS-6063 exposure. A similar Cmax was observed 
in the 400 and 600 mg BID dose cohorts on both Days 1 and 
15, and mean AUC values were relatively consistent across 
the 200–600 mg BID dose range. Clearance appeared to 
increase with dose on both Days 1 and 15, which is consist-
ent with the less than dose proportional increase in expo-
sure. Exposure at 400 mg BID (RP2D) was comparable to 
that previously reported in non-Japanese patients [9].
The best overall response in this study was stable dis-
ease, reported in 3 of the 9 patients, including 1 patient in 
each dose cohort. Durable stable disease of approximately 
24 weeks was observed in 1 subject with mesothelioma and 
1 subject with rectal cancer in the 400 and 600 mg dose 
cohorts, respectively. No objective radiographic responses 
were observed with VS-6063, which is similar to find-
ings with the first-generation compound PF-00562271 
[10] and another second-generation FAK inhibitors cur-
rently in development, GSK2256098 [15] and BI 853520 
[11, 12]. Inhibition of FAK prevents tumor invasion and 
dissemination rather than reducing tumor bulk. FAK inhi-
bition is not overtly cytotoxic and is expected to be most 
effective when used in combination with other chemo-
therapeutic drugs. Recent studies have suggested specific 
patient populations that may benefit from FAK inhibition. 
For example, in a signaling network involving extracellular 
signal-related kinase (ERK), RhoA and FAK are dysregu-
lated in high-grade non-small cell lung cancer (NSCLC) 
occurring against a background of Ink4a-Arf deficiency 
[16]. Suppression of RhoA or FAK selectively induced 
death in mutant Kras/Ink4a-Arf–deficient NSCLC cells, 
and pharmacologic inhibition of FAK caused regression 
of high-grade NSCLC in mutant Kras/Cdkn2a-null mice 
[16]. Based on these data, a study of VS-6063 has been 
initiated in patients with NSCLC harboring a Kras muta-
tion (ClinicalTrials.gov, NCT01951690). In addition, 
recent preclinical data revealed that FAK promotes anti-
tumor immune evasion. Specifically, the kinase activity of 
nuclear-targeted FAK in squamous cell carcinoma (SCC) 
cells drives exhaustion of CD8 + T cells and recruitment 
of regulatory T cells (Tregs) in the tumor microenviron-
ment by regulating chemokine/cytokine and ligand–recep-
tor networks, including via transcription of Ccl5, which is 
crucial. A small molecule FAK kinase inhibitor, VS-4718, 
which is currently in clinical development, also drives 
depletion of Tregs and promotes a CD8 + T cell-mediated 
anti-tumor response. Therefore, FAK inhibitors may trigger 
immune-mediated tumor regression, providing previously 
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unrecognized therapeutic opportunities [17]. These findings 
could be a strong rationale for combination strategy with 
FAK inhibitors and immune checkpoint inhibitors includ-
ing anti-PD-1 and anti-PD-L1 antibodies.
In summary, VS-6063 has an acceptable safety profile 
with Grade 1–2 adverse events that are easily managed and 
reversible, even with continued dosing, in Japanese subjects 
with advanced solid tumor malignancies. PK analyses con-
firmed that the exposure at the RP2D of 400 mg BID was 
comparable with that previously reported in non-Japanese 
subjects. Data from this study support VS-6063 administra-
tion to Japanese subjects with advanced solid tumor malig-
nancies in investigational trials. The favorable safety profile 
of VS-6063 creates the opportunity to combine this drug 
with other agents or to test it as monotherapy in the adju-
vant setting. For use as monotherapy, it will be important to 
identify suitable candidate populations [18–21].
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